{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T15:57:15Z","timestamp":1765555035768,"version":"3.48.0"},"reference-count":31,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Healthcare"],"abstract":"<jats:p>Background\/Objectives: To evaluate the cost-effectiveness of recombinant tumor necrosis factor receptor Fc fusion protein compared with methotrexate as first-line therapy for active rheumatoid arthritis in China using evidence from a Chinese head-to-head randomized trial. Methods: A Markov model with 6 months per cycle was developed to estimate costs and health utilization in the lifetime of patients with RA from the Chinese healthcare system. The analysis data were derived from the randomized clinical trial in China. The primary cost includes drug and other medical costs. The health utilities quality-adjusted life years (QALYs) were derived using EQ-5D-5L mapping from disease-specific health assessment questionnaire (HAQ) scores obtained in clinical trials. The cost-effectiveness analysis was conducted by calculating the incremental cost-effectiveness ratio (ICER) values for rhTNFR:Fc and MTX. One-way and probabilistic sensitivity analyses were conducted to test the robustness of the base-case result. Results: In the base case, rhTNFR:Fc yielded 8.20 QALYs versus 7.46 with methotrexate, resulting in an ICER of CNY 12,783.56 per QALY. Scenario ICERs for bDMARD group combination treatment were 11,776.31 per QALY. Scenario ICERs were CNY 8079.04 per QALY for the patient perspective and CNY 7630.34 per QALY for the medical insurance perspective. One-way analysis highlighted utility inputs as the main drivers, and probabilistic analysis indicated a high probability of cost-effectiveness across common willingness-to-pay thresholds. Conclusions: The fusion protein strategy achieved an incremental cost-effectiveness ratio far below the 2024 China per capita gross domestic product threshold of CNY 95,749 per quality-adjusted life year. As first-line therapy for active rheumatoid arthritis, it is cost-effective relative to methotrexate in the Chinese setting.<\/jats:p>","DOI":"10.3390\/healthcare13243267","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T15:27:20Z","timestamp":1765553240000},"page":"3267","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness Analysis of Recombinant Tumor Necrosis Factor Receptor: Fc Fusion Protein as First-Line Treatment for Active Rheumatoid Arthritis in China"],"prefix":"10.3390","volume":"13","author":[{"given":"Rui","family":"Zhang","sequence":"first","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aixia","family":"Ma","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid Arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40273-014-0174-6","article-title":"The Burden of Disease in Rheumatoid Arthritis","volume":"32","author":"Uhlig","year":"2014","journal-title":"PharmacoEconomics"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/art.40091","article-title":"Brief Report: Rheumatoid Arthritis as the Underlying Cause of Death in Thirty-One Countries, 1987-2011: Trend Analysis of World Health Organization Mortality Database","volume":"69","author":"Kiadaliri","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_4","first-page":"S852","article-title":"The Burden of Rheumatoid Arthritis","volume":"5","author":"Wolfe","year":"1999","journal-title":"Am. J. Manag. Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","article-title":"The Global Burden of Rheumatoid Arthritis: Estimates from the global Burden of Disease 2010 Study","volume":"73","author":"Cross","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1111\/1756-185X.13028","article-title":"Burden of Rheumatoid Arthritis from a Societal Perspective: A Prevalence-Based Study on Cost of This Illness for Patients in China","volume":"21","author":"Hu","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/acr.22160","article-title":"Societal Costs of Rheumatoid Arthritis in China: A Hospital-Based Cross-Sectional Study","volume":"66","author":"Xu","year":"2013","journal-title":"Arthritis Care Res."},{"key":"ref_8","unstructured":"National Collaborating Centre for Chronic Conditions (UK) (2009). Rheumatoid Arthritis: National Clinical Guideline for Management and Treatment in Adults. National Institute for Health and Clinical Excellence: Guidance, Royal College of Physicians."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res."},{"key":"ref_10","first-page":"357","article-title":"One Year in Review 2016: Novelties in the Treatment of Rheumatoid Arthritis","volume":"34","author":"Caterino","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"v22","DOI":"10.1093\/rheumatology\/kes115","article-title":"Optimizing Outcomes in Patients with Rheumatoid Arthritis and an Inadequate Response to Anti-TNF Treatment","volume":"51","author":"Emery","year":"2012","journal-title":"Rheumatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2022 Update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.1996.03530400035035","article-title":"Cost-Effectiveness of the Transdermal Nicotine Patch as an Adjunct to Physicians\u2019 Smoking Cessation Counseling","volume":"275","author":"Fiscella","year":"1996","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0895-4356(99)00021-9","article-title":"Incremental Cost-Effectiveness Analysis: The Optimal Strategy Depends on the Strategy Set","volume":"52","author":"Cantor","year":"1999","journal-title":"J. Clin. Epidemiol."},{"key":"ref_15","first-page":"61","article-title":"The Data Fitting and Optimal Control of a Hand, Foot and Mouth Disease (HFMD) Model with Stage Structure","volume":"276","author":"Li","year":"2016","journal-title":"Appl. Math. Comput."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Shen, M., Xiao, Y., Rong, L., Meyers, L.A., and Bellan, S.E. (2018). The Cost-Effectiveness of Oral HIV Pre-Exposure Prophylaxis and Early Antiretroviral Therapy in the Presence of Drug Resistance among Men Who Have Sex with Men in San Francisco. BMC Med., 16.","DOI":"10.1186\/s12916-018-1047-1"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00296-008-0681-x","article-title":"A Comparison Study of a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein (rhTNFR:Fc) and Methotrexate in Treatment of Patients with Active Rheumatoid Arthritis in China","volume":"29","author":"Hu","year":"2009","journal-title":"Rheumatol. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1515\/rir-2024-0028","article-title":"Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis: 2024 update","volume":"5","author":"Tian","year":"2025","journal-title":"Rheumatol. Immunol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.autrev.2012.11.009","article-title":"Cost-Effectiveness of Biologic Treatment for Rheumatoid Arthritis in Clinical Practice: An Achievable Target?","volume":"12","author":"Modena","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_20","first-page":"238","article-title":"Assessment of Long-Term Safety and Efficacy of Etanercept in a 5-Year Extension Study in Patients with Rheumatoid Arthritis","volume":"29","author":"Klareskog","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_21","first-page":"S237","article-title":"Improved Health-Related Quality of Life with Effective Disease-Modifying Antirheumatic Drugs: Evidence from Randomized Controlled Trials","volume":"13","author":"Strand","year":"2007","journal-title":"Am. J. Manag. Care"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a Fully Human Anti-Tumor Necrosis Factor Alpha Monoclonal Antibody, for the Treatment of Rheumatoid Arthritis in Patients Taking Concomitant Methotrexate: The ARMADA Trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 Receptor Inhibition with Tocilizumab Improves Treatment Outcomes in Patients with Rheumatoid Arthritis Refractory to Anti-Tumour Necrosis Factor Biologicals: Results from a 24-Week Multicentre Randomised Placebo-Controlled Trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1109071","article-title":"Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Yu, B., Qiao, L., Li, L., Zuo, K., Li, L., Wang, L., Jiang, N., Wang, Q., Li, M., and Wang, Y. (2025). Average Annual Costs of Rheumatoid Arthritis Estimated by Inverse Probability Weighting and Their Influence Factors: A Cross-Sectional Study Based on Chinese Registry of Rheumatoid Arthritis (CREDIT) Cohort. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0330261"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wan, C., Wang, Q., Xu, Z., Huang, Y., and Xi, X. (2023). Mapping Health Assessment Questionnaire Disability Index onto EQ-5D-5L in China. Front. Public Health, 11.","DOI":"10.3389\/fpubh.2023.1123552"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/13696998.2017.1307205","article-title":"Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators","volume":"20","author":"Jansen","year":"2017","journal-title":"J. Med Econ."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Wu, B., Wilson, A., Wang, F.-F., Wang, S.-L., Wallace, D.J., Weisman, M.H., and Lu, L.-J. (2012). Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in China. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047373"},{"key":"ref_30","first-page":"20","article-title":"Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: A cost-effectiveness analysis in the era of biosimilars","volume":"33","author":"Wu","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e2418800","DOI":"10.1001\/jamanetworkopen.2024.18800","article-title":"Cost-effectiveness of biosimilars vs leflunomide in patients with rheumatoid arthritis","volume":"7","author":"Peng","year":"2024","journal-title":"JAMA Netw. Open"}],"container-title":["Healthcare"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9032\/13\/24\/3267\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T15:35:50Z","timestamp":1765553750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9032\/13\/24\/3267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":31,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["healthcare13243267"],"URL":"https:\/\/doi.org\/10.3390\/healthcare13243267","relation":{},"ISSN":["2227-9032"],"issn-type":[{"value":"2227-9032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]}}}